Clinical Trial Update: Effects of Selexipag in Adults With Raynaud's Phenomenon Secondary to Systemic Sclerosis [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating selexipag for Raynaud's phenomenon in adults with systemic sclerosis. The study status is completed.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Raynaud Phenomenon
• Systemic Sclerosis

Drugs mentioned

• Selexipag (selexipag)

Snippet

Sponsor: Actelion | Conditions: Raynaud's Phenomenon Secondary to Systemic Sclerosis | Phase 2 | Status: COMPLETED